Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRangi Kandane-Rathnayakeen_US
dc.contributor.authorVera Golderen_US
dc.contributor.authorWorawit Louthrenooen_US
dc.contributor.authorShue Fen Luoen_US
dc.contributor.authorYeong Jian Jan Wuen_US
dc.contributor.authorZhanguo Lien_US
dc.contributor.authorYuan Anen_US
dc.contributor.authorAisha Lateefen_US
dc.contributor.authorSargunan Sockalingamen_US
dc.contributor.authorSandra V. Navarraen_US
dc.contributor.authorLeonid Zamoraen_US
dc.contributor.authorLaniyati Hamijoyoen_US
dc.contributor.authorYasuhiro Katsumataen_US
dc.contributor.authorMasayoshi Harigaien_US
dc.contributor.authorMadelynn Chanen_US
dc.contributor.authorSean O’Neillen_US
dc.contributor.authorFiona Goldblatten_US
dc.contributor.authorYanjie Haoen_US
dc.contributor.authorZhuoli Zhangen_US
dc.contributor.authorJamal Al-Salehen_US
dc.contributor.authorMunther Khamashtaen_US
dc.contributor.authorTsutomu Takeuchien_US
dc.contributor.authorYoshiya Tanakaen_US
dc.contributor.authorSang Cheol Baeen_US
dc.contributor.authorChak Sing Lauen_US
dc.contributor.authorAlberta Hoien_US
dc.contributor.authorMandana Nikpouren_US
dc.contributor.authorEric F. Moranden_US
dc.description.abstract© 2018 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd Aim: The aim of this manuscript is to describe the development of the Asia Pacific Lupus Collaboration (APLC) cohort. Method: The APLC cohort is an ongoing, prospective longitudinal cohort. Adult patients who meet either the American College of Rheumatology (ACR) Modified Classification Criteria for systemic lupus erythematosus (SLE), or the Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria, and provide informed consent are recruited into the cohort. Patients are routinely followed up at 3- to 6-monthly intervals. Information on demographics, clinical manifestations, treatment, pathology results, outcomes, and patient-reported quality of life (Short-form 36 version 2) are collected using a standardized case report form. Each site is responsible for obtaining local ethics and governance approval, patient recruitment, data collection, and data transfer into a centralized APLC database. Results: The latest APLC cohort comprises 2160 patients with >12 000 visits from Australia, China, Hong Kong, Indonesia, Japan, Malaysia, Philippines, Singapore, Taiwan and Thailand. The APLC has proposed the Lupus Low Disease Activity State (LLDAS) as a treat-to-target (T2T) endpoint, and reported several retrospective and cross-sectional analyses consistent with the validity of LLDAS. Longitudinal validation of LLDAS as a T2T endpoint is currently underway. Conclusion: The APLC cohort is one of the largest contemporary SLE patient cohorts in the world. It is the only cohort with substantial representation of Asian patients. This cohort represents a unique resource for future clinical research including evaluation of other endpoints and quality of care.en_US
dc.titleDevelopment of the Asia Pacific Lupus Collaboration cohorten_US
article.title.sourcetitleInternational Journal of Rheumatic Diseasesen_US Universityen_US Mai Universityen_US Gung Memorial Hospitalen_US University Health Science Centeren_US University Hospital, Singaporeen_US of Malayaen_US of Santo Tomas Hospitalen_US of Padjadjaranen_US Women's Medical Universityen_US Tock Seng Hospitalen_US Hospitalen_US Adelaide Hospitalen_US Medical Centreen_US Universityen_US Hospitalen_US University School of Medicineen_US of Occupational and Environmental Healthen_US Universityen_US University of Hong Kongen_US Vincent's Hospital Melbourneen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.